Eikon Therapeutics Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Employees
  • 100
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $518M
Latest Deal Amount
  • Investors
  • 19

Eikon Therapeutics General Information

Description

Developer of a drug discovery platform designed to offer a novel treatment for life-threatening diseases. The company's platform facilitates sensitive identification of compounds-protein interactions that could not be identified through traditional assays, by directly measuring the effects of chemical compounds on the behavior of a wide array of individual proteins in a live cellular environment, enabling companies to unlock the otherwise intractable classes of proteins as drug targets.

Contact Information

Website
www.eikontx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 3929 Point Eden Way
  • Hayward, CA 94545
  • United States
+1 (341) 000-0000

Eikon Therapeutics Timeline

202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eikon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 06-Jan-2022 $518M 00000 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 05-May-2021 00000 00000 00000 Completed Generating Revenue
To view Eikon Therapeutics’s complete valuation and funding history, request access »

Eikon Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series A-1 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series A 48,000,000 $0.000100 $0.06 $1 $1 1x $1 28.13%
To view Eikon Therapeutics’s complete cap table history, request access »

Eikon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery platform designed to offer a novel treatment for life-threatening diseases. The company's
Drug Discovery
Hayward, CA
100 As of 2022
00000
0.000 0000-00-00
00000000000 00000

00000000

tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
San Francisco, CA
00.00
000000&0 00.00

00000000

o laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000 000000000
Kent, United Kingdom
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eikon Therapeutics Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Haystack Sciences Formerly VC-backed San Francisco, CA 00.00 000000&0 00.00
00000000 000000000 Venture Capital-Backed Kent, United Kingdom 0 000.00 00000000000 000.00
00000000 Formerly VC-backed Waltham, MA 00 00000 000000&0 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 Venture Capital-Backed San Francisco, CA 000 00000 0000000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Eikon Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Roger Perlmutter President, Chief Executive Officer & Chairman
Alfred Bowie Ph.D Chief Financial Officer
Ashish Kheterpal Chief Information Officer
Daniel Anderson Ph.D Chief Scientific Officer
Benjamin Thorner Chief Commercial Officer & General Counsel
You’re viewing 5 of 11 executive team members. Get the full list »

Eikon Therapeutics Board Members (5)

Name Representing Role Since
Adam Goulburn Ph.D Self Board Member 000 0000
Dror Berman Self Board Member 000 0000
James Tananbaum MD Foresite Capital Management Board Member 000 0000
Leon Chen Ph.D Self Board Member 000 0000
Roger Perlmutter Eikon Therapeutics President, Chief Executive Officer & Chairman 000 0000
To view Eikon Therapeutics’s complete board members history, request access »

Eikon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eikon Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AME Cloud Ventures Venture Capital Minority 000 0000 000000 0
Canada Pension Plan Investment Board Limited Partner Minority 000 0000 000000 0
E15 VC Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
General Catalyst Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial